Headquartered in Franklin Lakes, NJ Fiscal year ends September NYSE: BDX bd.com
Becton, Dickinson and Company (BD) is one of the world's largest pure-play medical technology companies, focused on advancing health through innovation across four business segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional. Following the February 2026 spin-off of its Biosciences and Diagnostic Solutions business (combined with Waters Corporation), BD operates as 'New BD' with a streamlined focus on MedTech. The company develops and manufactures medical devices, instrument systems, and reagents used by healthcare institutions, clinical laboratories, pharmaceutical companies, and the general public. Key product areas include medication delivery solutions, specimen management, medication management systems, advanced patient monitoring, pharmaceutical delivery systems (including injection pens for GLP-1 therapies), peripheral intervention devices, urology and critical care products, and surgical instruments. BD employs more than 60,000 people globally and delivers billions of products annually that impact healthcare worldwide. Updated
Pacemakers and glucose monitors keep selling whether the economy booms or collapses, and three medical device giants have spent decades turning that predictable demand into paychecks that grow every single year. One…
Two brutal recessions wiped out dividends across the market, yet a handful of healthcare companies kept raising their payouts through every quarter of both downturns. Here are the four names that made…
Jim Cramer just put a Brazilian mining giant in the same sentence as cryptocurrency, and his reasoning has everything to do with where he thinks inflation is headed next.
Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where…
Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made…
Wall Street has gotten far more selective on AI stocks, but these AI stocks are still receiving the lion’s share of invested capital. Dividend Aristocrat stocks like PepsiCo (NASDAQ:PEP | PEP Price…
Dividend Kings are stocks that’ve had their dividend payouts raised for 50 consecutive years or more, such as Target (NYSE:TGT | TGT Price Prediction), Becton Dickinson (NYSE:BDX), and Hormel Foods (NYSE:HRL). That…
Dividend Aristocrats are some of the best stocks to buy when they go on sale, as they’re backed by companies on a solid footing. These companies have raised the dividends on their…
Wall Street feels these five Dividend Aristocrat stocks are the best values in the group and offer the best entry points for investors seeking dependable income with growth potential.
With all of the attention focused on the Magnificent 7 tech stocks, AI, and biotech stocks that are all high flying and turbo charging the S&P 500, it’s easy to overlook other…
As we enter the second half of 2025, now is the perfect time to invest in dividend stocks — especially those with quality underlying fundamentals that pay high dividend yields. Many such…
Certain stocks have declined significantly in the past few months as the economic cycle has been changing. The Federal Reserve seems well-positioned to do at least one rate cut this year. Inflation…
Live Updates Amazon Works to Keep the Bubble Afloat4:09pm ETAnd that’s a wrap for Thursday. The market has closed, and the S&P 500 ended up hanging on to most of its gains…
Tuesday's top analyst upgrades and downgrades included American Express, Apple, AppLovin, Conagra Brands, D.R. Horton, Estee Lauder, Juniper Networks, Livent, Microsoft, Netflix, Nvidia, Shopify, Tesla, and Twilio.
Wednesday's top analyst upgrades and downgrades included Abbott Laboratories, Boston Scientific, ChargePoint, Coinbase Global, Dollar General, Equitrans Midstream, Ford, Hasbro, Johnson & Johnson, Kenvue and Medtronic.
Becton, Dickinson and Company (BD) is one of the world's largest pure-play medical technology companies, focused on advancing health through innovation across four business segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional.
24/7 Wall St.'s 12-month price target for BDX is $205.77, rated Buy. The Wall Street consensus target is $194.08. BDX price prediction →
